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Abstract
The development of an effective malaria vaccine is a high global health priority. Vaccine vectors based on adenovirus type 5
are capable of generating robust and protective T cell and antibody responses in animal models and are currently being
evaluated in clinical trials for HIV and malaria. They appear to be more effective in terms of inducing antigen-specific
immune responses as compared with non-Ad5 serotype vectors. However, the high prevalence of neutralizing antibodies to
Ad5 in the human population, particularly in the developing world, has the potential to limit the effectiveness of Ad5-based
vaccines. We have generated novel Ad5-based vectors that precisely replace the hexon hypervariable regions with those
derived from Ad43, a subgroup D serotype with low prevalence of neutralizing antibody in humans. We have demonstrated
that these hexon-modified adenovectors are not neutralized efficiently by Ad5 neutralizing antibodies in vitro using sera
from mice, rabbits and human volunteers. We have also generated hexon-modified adenovectors that express a rodent
malaria parasite antigen, PyCSP, and demonstrated that they are as immunogenic as an unmodified vector. Furthermore, in
contrast to the unmodified vector, the hexon-modified adenovectors induced robust T cell responses in mice with high
levels of Ad5 neutralizing antibody. We also show that the hexon-modified vector can be combined with unmodified Ad5
vector in prime-boost regimens to induce protective responses in mice. Our data establish that these hexon-modified
vectors are highly immunogenic even in the presence of pre-existing anti-adenovirus antibodies. These hexon-modified
adenovectors may have advantages in sub-Saharan Africa where there is a high prevalence of Ad5 neutralizing antibody in
the population.
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Introduction
Recombinant adenoviruses have been developed as an efficient,
replication-defective gene delivery vector [1,2,3,4,5]. Vaccination
with adenovirus type 5 (Ad5) vectors carrying disease-specific
antigens results in the induction of broad and protective T cell and
antibody responses in a number of animal models, ranging from
mouse to non-human primate [6,7,8,9,10,11,12,13,14,15,16]. In
one example, an Ad5 vector encoding the Ebola surface
glycoprotein generated neutralizing antibodies and protected
monkeys following a single administration [10]. Protection from
malaria has also been observed using adenovectors that express the
circumsporozoite (CSP) antigen in the Plasmodium yoelii [12,17,18]
or Plasmodium berghei [19] murine models. Adenovectors are
currently being evaluated in clinical trials for vaccines against
HIV [20,21,22], tuberculosis [23], and malaria [24,25,26]. The
Ad5-based HIV and malaria vaccines have been well tolerated
and induced antigen-specific CD4+ T cell, CD8+ T cell, and
antibody responses in a majority of volunteers [20], [25,26].
Forty to sixty percent of the United States population have
neutralizing antibodies to Ad5 [27,28] and the frequency is even
higher in Africa, where malaria is endemic [29,30,31]. In animal
models, including mice [32] and non-human primates [33], prior
exposure to Ad5 diminished T cell responses to the target antigen
following immunization with an Ad5 vector. As expected, due to
the type specificity of adenovirus neutralizing antibody (NAb) [34],
pre-existing Ad5 NAb were not effective in reducing vaccine-
induced responses to other adenovirus vaccines based on
alternative human [27,35] or simian [36,37,38,39] serotypes.
Unfortunately, adenovectors derived from alternative human or
simian serotypes have generally underperformed Ad5-based
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vectors with regard to induction of antigen-specific immune
responses [3,17,32,35,40,41].
Reports addressing the impact of pre-existing Ad5 NAb on
adenovector vaccine immunogenicity in humans indicate that
volunteers possessing high titers of Ad5 NAb were capable of
mounting significant antigen-specific humoral [20] and cellular
responses [20,22]. However, the magnitude and frequency of T
cell responses in individuals with pre-existing Ad5 neutralizing
antibodies was lower than those observed in Ad5-seronegative
volunteers. Overall, these results suggest that adenovectors that are
not inhibited by pre-existing adenovirus NAb are likely to have an
advantage with respect to vaccine efficacy.
Adenovirus virions are composed of non-enveloped icosahedral
shaped capsids that surround the viral DNA-protein core complex.
Hexon is the most abundant structural protein, with 240 copies of
the trimeric molecule per capsid. Twelve copies of the hexon
trimer form each of the 20 triangular facets of the capsid. A
complex of penton base and fiber proteins seals the vertices of the
capsid and facilitates attachment (fiber) and internalization
(penton base) of the virus [42]. Adenovirus-specific NAb have
been identified that target hexon, fiber and penton base [43,44].
However, studies with chimeric adenoviruses have shown that the
hexon is the major target for NAb that functions in vivo [31,45,46].
These findings suggest the potential for generating chimeric
capsids composed of hexons from different serotypes as a way of
generating adenovectors that avoid pre-existing Ad5 NAb. Ad5
vectors are capable of incorporating hexons from other subgroup
C serotypes or Ad12, but hexons from other species (for example,
Ad4, Ad7, Ad9, Ad13, Ad17 and Ad35) have not been viable in
the context of the Ad5 virion [47]. These results suggest serotype-
specific interactions between hexon and other capsid components.
An alternative strategy for the generation of Ad5 vectors that avoid
pre-existing NAb is, therefore, to modify only the regions of the
hexon protein that are the targets of serotype-specific NAb.
The hexon protein is highly conserved among the different
adenovirus serotypes with the exception of nine hypervariable
regions (HVRs) [48]. Analysis of the crystal structures of Ad2 and
Ad5 has shown that these HVRs reside in two distinct loops that
form the exposed surface of the hexon protein [48,49,50]. HVRs
1–6 lie within the DE1 loop and HVRs 7–9 are located within the
FG1 loop. Ad5 vectors carrying substitution of the DE1 and FG1
loops from Ad2, or Ad12 are not neutralized efficiently by Ad5
NAb [46,51] indicating that these hypervariable loops contain the
targets of type-specific neutralizing antibodies. One group of
researchers has demonstrated that it is possible to replace each of
the 9 HVRs of the Ad5 hexon with those derived from Ad48, a
rare adenovirus serotype [52]. Induction of transgene-specific
immune responses was unaffected by Ad5-specific NAb in murine
or non-human primate vaccine models. Here, we have evaluated
the potential of novel Ad5-based vectors where the hexon
hypervariable regions are replaced with those derived from
alternate serotypes with low prevalence of neutralizing antibody
in humans, specifically Ad43 (group D) and Ad34 (group B).
Results
Ad5 vectors are tolerant of intersubgroup exchanges in
the FG1, but not the DE1 surface exposed loops of hexon
We reasoned that substitution of the HVRs in the Ad5 hexon with
those derived from less prevalent serotypes would result in a vaccine
vector with the potency of Ad5 that would not be inhibited by pre-
existing Ad5 NAb. Accordingly we designed and cloned three hybrid
vectors with hexon HVRs based on the group C (Ad2); group D
(Ad43); and group B (Ad34). The Ad2 HVRs were chosen as a positive
control as chimeric hexons derived from Ad2 and Ad5 have been
successfully generated previously [46]. Ad34 and Ad43 were chosen
due to their low seroprevalence in human populations [27]. Initially,
we attempted to substitute the complete Ad5 DE1 loop, containing
HVRs 1–6 and the complete FG1 loop containing HVRs 7–9, with
comparable loops derived from Ad2, Ad43 and Ad34 (Figure 1 and
Figure S1). We successfully rescued recombinant adenovectors
carrying the FG1 hypervariable loop substitutions (Figure 1). DE1
loop substitutions were not tolerated to the same degree. Multiple
attempts to generate recombinant adenovector from plasmid
constructs carrying the Ad43, or Ad34 DE1 loop substitutions did
not result in the rescue of viable hybrid vectors. Only the Ad2 DE1
loop exchange was capable of being converted into a virus vector
(Figure 1). However, due to the high seroprevalence of Ad2 in human
populations [27], generation of chimeric vectors with HVRs from less
prevalent adenovector serotypes is preferred.
Generation of a chimeric Ad5 vector containing all nine
hexon HVRs from Ad43
The DE1 loop is composed of six HVRs and their intervening
sequences, which are more highly conserved across serotypes. The
intervening sequences are more highly conserved between the two
group C hexons (Ad2 and Ad5) than they are between Ad5 and
the group D or group B hexons (Ad43 or Ad34). This is not the
case for the HVRs themselves, which are highly divergent between
Ad5 and Ad2. We reasoned that the sequences adjacent to the
HVRs within the DE1 loop may be important for maintaining a
well structured capsid and that the more homologous Ad2
sequences could function in an Ad5 hexon, but the divergent
Ad34 and Ad43 HVR flanking sequences could not. We therefore
focused on precisely exchanging the presumed targets of type-
specific NAb, the six small HVRs within the DE1 loop of Ad5
hexon, with those derived from Ad43. Using this strategy, we were
successful at generating Ad5 vectors carrying HVRs 1–9 from
Ad43, and the intervening sequences from Ad5 (Figure 2 and
Figure S2). We generated hexon-modified vectors that express
PyCSP and luciferase for use in immunogenicity and in vitro
neutralization studies, respectively. Chimeric vectors were gener-
ated that contained the Ad43 sequence substitutions in the DE1
loop, the FG1 loop, or both loops. All of these hexon-modified
vectors had particle:active particle ratios of ,50 which are
comparable to vectors with unmodified hexons (Table S1). To
assess capsid protein composition, we compared the protein
pattern of vectors with unmodified and hexon-modified capsids on
silver stained gels. This analysis indicated that the protein
composition of our hexon-modified vectors is comparable to
wild-type Ad5 as well as Ad5 vectors with wild-type hexons (Figure
S3). We analyzed transgene expression following infection of A549
cells. Cells were transduced with 200 particle units (pu) per cell of
the unmodified or hexon-modified PyCSP expressing vectors.
PyCSP expression was evaluated 24 hours later by immunoblots
from infected cell lysates (Figure 2b). The positive control for this
western blot (ScPyCSP) is purified PyCSP protein from yeast and
the extra band is likely a degradation product of the full length
protein. Our results show that comparable levels of PyCSP are
expressed from the unmodified Ad5 vector and from each of the
hexon-modified vectors in vitro.
Ad5 hexon-modified vector containing Ad43
substitutions in all nine HVRs is not neutralized efficiently
by Ad5 NAb
To assess the ability of Ad5 NAb to neutralize the chimeric
vector, we generated NAb in mice. Mice were immunized with
Hexon Modified Ad Vector
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Figure 1. Generation of Ad5 vectors with chimeric hexons derived from Ad2, Ad43 and Ad34. A schematic view of the Ad5 hexon protein
and viable chimeric vectors is shown. The positions of surface loops (DE1 and FG1) within the hexon protein are indicated. The HVRs 1–9, indicated in
black, are shown above the Ad5 hexon. Sequences from Ad5 are indicated in white, Ad2 in diagonal stripes, Ad34 in gray and Ad43 in black. Viable
vectors produced were: Ad5H(5–5) containing the wild-type Ad5 hexon; Ad5H(2–2) containing the Ad2 DE1 and FG1 loops; Ad5H(5–43) containing
the FG1 loop from Ad43; and Ad5H(5–34) containing the FG1 loop from Ad34.
doi:10.1371/journal.pone.0033920.g001
Figure 2. Ad5 vectors containing hexon hypervariable regions from Ad43 express PyCSP transgene efficiently. Generation of Ad5
vectors with hypervariable regions of Ad43. A. Schematic showing the DE1 and FG1 loops of the unmodified Ad5 vector and three chimeric vectors
containing Ad43 HVR substitutions in the FG1 loop, DE1 loop and both loops as indicated. B. Western blot showing the expression of the PyCSP
antigen following infection of A549 cells with 200 pu/cell of purified vectors. Mock represents an uninfected cell lysate and serves as a negative
control. ScPyCSP represents purified PyCSP protein from Saccharomyces cerevisiae and serves as a positive control. Hexon designations are indicated
above the associated well (H = hexon) and the serotype source of the DE1 and FG1 loops shown in parentheses (DE1–FG1). Immunoblots were
probed with antibody specific for PyCSP.
doi:10.1371/journal.pone.0033920.g002
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two administrations (161010 pu each) of Ad5 vector at an interval
of one month and the serum from these mice was tested for
neutralizing activity against an unmodified Ad5 vector that
expresses luciferase (Ad5L) or the chimeric hexon-modified
luciferase vector (Ad5L.H(43 m-43). This serum efficiently
neutralized the Ad5 vector but was less effective at neutralizing
the hexon-modified vector (Figure 3, Ad5 serum). To determine if
the residual neutralizing activity observed in the hexon-modified
vector was due to NAb specific for the Ad5 fiber, we generated
NAb from mice using an Ad5 vector containing an Ad35 fiber.
Serum from these mice neutralized the Ad5 vector, but did not
neutralize the hexon-modified vector (Figure 3, Ad5.F(35) serum).
The neutralizing activity of the full serial dilution series is shown in
Figure S4. In control experiments, we immunized mice with Ad43
and observed that these sera neutralized the Ad5L.H(43 m-43),
but not Ad5L (data not shown). These data indicate that
neutralizing antibodies specific for both the hexon HVRs and
the fiber are functional in vitro.
To expand the in vitro vector neutralization studies, we analyzed
NAb responses from rabbits and humans against a panel of
chimeric adenovectors (Figure 4). Four luciferase expressing Ad5
vectors were analyzed to differentiate NAb responses specific for
the Ad5 HVRs, the Ad5 fiber, or other Ad5 capsid components.
Ad5L has a wild-type Ad5 capsid. Ad5L.H(43 m-43) contains nine
HVRs from Ad43. Ad5L.F(35) contains the Ad35 fiber.
Ad5L.H(43 m-43)F(35) contains nine HVRs from Ad43 and the
fiber from Ad35. Rabbits were immunized with two doses
(161010 pu each) of Ad5Null vector at a one month interval and
the serum from individual rabbits was harvested one month after
the last administration and tested for its capacity to neutralize the
chimeric adenovectors. Neutralization titers for Ad5L ranged from
2,048 to 131,072. In all six rabbits, Ad5L.H(43 m-43) was
neutralized less efficiently than Ad5L (p,0.05) indicating the
existence of NAb specific for the Ad5 HVRs. There was a trend
toward reduced neutralization of Ad5L.F(35) relative to Ad5L. In
50% of the rabbits (rabbits 1, 2 and 6), Ad5L.F(35) was neutralized
less efficiently than Ad5L indicating the existence of NAb specific
for the Ad5 fiber in these animals (Figure 4a). However, in the
other 50% of the animals (rabbits 3, 4 and 5), Ad5L.F(35) and
Ad5L were neutralized equally well indicating that all of the
neutralization measured in this assay can be accounted for by non-
fiber capsid components. In all six rabbits, there was a dramatic
drop in NAb titer to Ad5L.H(43 m-43).F(35) relative to Ad5L,
Ad5L.H(43 m-43), and Ad5L.F(35) (p,0.05). In one of the six
rabbits (rabbit 6), no Ad5L.H(43 m-43).F(35)-specific Nab were
detected. These data show that most of the adenovirus NAb
generated in rabbits immunized with Ad5 vectors is specific for the
hexon HVRs and the fiber and that there is a relatively low
concentration of NAb directed to other capsid components. We
hypothesize that fiber-specific NAb were not revealed in rabbits 3,
4, and 5 by comparing Ad5L to Ad5L.F(35) because in these
animals the titer of the fiber-specific NAb is much lower than that
of the hexon-specific NAb. Comparison of the NAb titers for
Ad5L.H(43 m-43) and Ad5L.H(43 m-43)F(35), reveals that fiber-
specific NAb account for an appreciable component of the total
NAb titer when the dominant HVR-specific NAb are rendered
non-functional.
Next, we analyzed serum from a population of 25 human
volunteers from Gaithersburg, MD (Figure 4b). Ad5-specific NAb
were detected in 11 individuals. Serum samples from 10
individuals had titers ranging from 256 to 4096 and one sample
had a titer between 16 and 48. Sera from individuals that were
negative for Ad5 NAb (titer,16) and from this individual with low
titer Ad5 NAb were not included in the analysis shown in
Figure 4b. Ad35-specific NAb were detected in four of the 25
individuals, two of which were also positive for Ad5 NAb. Analysis
of the capacity of serum NAb to neutralize the chimeric vectors
indicated that most of the NAb in humans are directed to the
hexon HVRs and fiber and only a minority to other capsid
components, consistent with the results in rabbits. Specifically, in
most of the volunteers (7/10), Ad5L.H(43 m-43) was neutralized
less efficiently than Ad5L (p,0.05) indicating the existence of NAb
specific for the Ad5 HVRs. In 6/10 of the volunteers, Ad5L.F(35)
was neutralized less efficiently than Ad5L (p,0.05) indicating the
existence of NAb specific for the Ad5 fiber in these individuals
(Figure 4b). However, in the other volunteers (4/10), Ad5L.F(35)
and Ad5L were neutralized equally well indicating that all of the
neutralization measured in this assay can be accounted for by non-
fiber capsid components. In all 10 volunteers, there was a large
drop in NAb titer to Ad5L.H(43 m-43).F(35) relative to Ad5L
(p,0.05) indicating that NAb specific for both hexon and fiber
dominate the anti-Ad5 NAb response in these volunteers. In some
volunteers (039, 052, 024 and 025) fiber-specific NAb are only
revealed by rendering hexon-specific NAb non-functional and
comparing Ad5L.H(43 m-43).F(35) and Ad5L.H(43 m-43). Simi-
larly, in other volunteers (033, 005, 014) hexon-specific NAb are
only revealed by rendering fiber-specific NAb non-functional and
comparing Ad5L.H(43 m-43).F(35) and Ad5L.F(35).
Ad5 hexon-modified vector containing Ad43
substitutions in all nine HVRs induces robust PyCSP-
specific CD8+ T cell responses in mice with high titers of
Ad5 specific NAb
To assess the immunogenicity of hexon-modified Ad5 vectors
expressing PyCSP, we compared induction of T cell responses in
mice immunized with unmodified and hexon-modified vectors.
BALB/c mice were immunized with 16108 pu of adenovector
expressing PyCSP (Figure 5a). Antigen specific T cell responses
Figure 3. Ad5L.H(43-43) is not neutralized efficiently by Ad5
NAb from mice. Mice were immunized with two administrations
(161010 pu each) of adenovector at an interval of one month. The
serum from these mice obtained three weeks after the last
immunization was pooled, diluted 1:48 and then 3-fold serial dilutions
were tested for neutralizing activity toward an unmodified Ad5L vector
and the Ad5L.H(43 m-43) hexon-modified vector. Two different
adenovectors were used to immunize mice and generate serum, an
Ad5 vector (Ad5) and an Ad5 vector with an Ad35 fiber replacement
(Ad5.F35).
doi:10.1371/journal.pone.0033920.g003
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were evaluated by intracellular cytokine staining (ICS) (Figure 5b)
and by IFNc ELISpot (Figure 5c) and PyCSP-specific antibody
responses were assessed by ELISA (Figure 5d). For both the
unmodified and hexon-modified vectors we observed robust
induction of PyCSP-specific IFNc+CD8+ T cell and antibody
responses four weeks following immunization. T cell responses
were specific for both the immunodominant (PyCSP 280–288) and
subdominant (PyCSP 57–70) CD8+ T cell epitopes and there were
no statistically significant differences in CSP-specific T cell
responses between the unmodified and hexon-modified vectors.
To determine the effect of pre-existing Ad5 NAb on the
immunogenicity of these vectors, mice were pre-immunized with
two administrations (161010 pu each), one month apart, of Ad5
vector (Ad5L) or an Ad5 vector containing an Ad35 fiber
(Ad5L.F(35)). Under these conditions, the unmodified vector,
Ad5PyCSP, was substantially reduced in its capacity to induce
PyCSP-specific T cell and antibody responses as indicated by ICS,
ELISpot and ELISA. In contrast, the Ad43 hexon-modified
vector, AdCSP.H(43 m-43), induced significantly higher PyCSP-
specific T cell responses in mice pre-immunized with Ad5 vectors
versus the unmodified vector, AdCSP(Figure 5b and c; p,0.05).
However, we observed a small but significant reduction in CSP-
specific CD8+ T cells induced by AdCSP.H(43 m-43) in mice pre-
immunized with Ad5 vector relative to naı¨ve mice (p,0.05). The
hexon-modified vector also induced PyCSP-specific antibody
responses in mice pre-immunized with Ad5 vectors, although
these responses were reduced relative to the antibody responses
induced in mice not previously exposed to Ad5 vectors (Figure 5d).
There was no difference in the PyCSP-specific T cell or antibody
responses induced by PyCSP.H(43 m-43) in mice pre-immunized
with Ad5 vector or Ad5 vector with the Ad35 fiber, suggesting that
antibody to fiber does not reduce the immunogenicity of the
Ad5PyCSP.H(43 m-43) vector in mice (Figure 5).
Analysis of immunogenicity and protection from P. yoelii
sporozoite challenge following immunization of mice
with Ad5PyCSP.H(43 m-43) and Ad5PyCSP in prime-
boost regimens
We have demonstrated that a hexon-modified Ad5 vector can
effectively boost an unmodified Ad5 vector primed immune
response, generating more robust T cell and antibody responses
than either vector administered alone when administered at low
doses (Figure S5). To determine if an Ad5 hexon-modified prime-
Ad5 unmodified boost regimen is capable of inducing protective
immune responses, we immunized mice with 16109 pu of
Ad5PyCSP.H(43 m-43) followed by a boost six weeks later with
Ad5PyCSP and measured sterile protection following P. yoelii
sporozoite challenge (Table 1) as well as T cell and antibody
responses (Figures 6 and 7). In parallel, we evaluated mice primed
with PyCSP expressing plasmid DNA (DNA-PyCSP), Ad5PyCSP,
Ad28PyCSP or Ad35PyCSP and then boosted with Ad5PyCSP.
Two weeks after the Ad5PyCSP boost, mice were challenged by
intravenous (IV) injection with 100 freshly dissected P. yoelii
sporozoites. Blood stage parasitemia was scored following daily
blood smears from day 7–14. Our results show negligible
protection with either one or two doses of the Ad5PyCSP vector
(0% and 14%, respectively). However, we saw statistically
significant protection with each of the heterologous prime-boost
regimens tested (Table 1). The DNA prime-Ad5 boost regimen
protected 36% of mice. There was a trend toward higher levels of
protection in the heterologous adenovector prime-boost regimens,
with the Ad5PyCSP.H(43 m-43) prime-Ad5PyCSP boost, Ad28
prime-Ad5 boost and Ad35 prime-Ad5 boost, protecting 43, 54
and 46% of mice, respectively. These data establish that
heterologous adenovector prime-boost regimens can induce
protective responses in mice and also show that hexon-modified
Ad5 vector can be combined with an unmodified Ad5 vector in an
effective prime-boost regimen.
All vaccine prime-boost regimens tested (DNA/Ad and Ad/Ad)
induced robust IFNc ELISpot responses directed against peptides
containing the CD8+ dominant epitope (PyCSP280–288 and
Figure 4. NAb directed at both HVRs and fiber are dominant in
vitro. Sera from (A) rabbits immunized with two administrations of
161010 pu of AdNull or (B) human volunteers screened for the presence
of neutralizing antibodies specific for Ad5 were analyzed for NAb titers
against a panel of chimeric adenovectors expressing the luciferase
reporter gene. Ad5L is an unmodified Ad5 vector; Ad5L.H(43 m-43) is a
hexon-modified Ad5 vector containing HVRs 1–9 from Ad43; Ad5L.F35
is an Ad5 vector carrying the Ad35 fiber; Ad5L.H(43 m-43).F35 is a
hexon-modified vector carrying the Ad35 fiber. The asterisk indicates
serum samples that scored positive for Ad35-specific NAb.
doi:10.1371/journal.pone.0033920.g004
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PyCSP280–296) (Figure 6b). The heterologous adenovector
prime/boost regimens induced PyCSP antibody titers comparable
to DNA/Ad5-PyCSP and higher titers than Ad5/Ad5-PyCSP and
Ad5-PyCSP alone regimens (Figure 6c). Protective regimens
(p,0.05) induced higher PyCSP-specific antibody titers (.4500
titer at OD 0.5) 10 days post-boost as compared with the non-
protective regimens. DNA/Ad5, Ad5.H43/Ad5, Ad28/Ad5, and
Ad35/Ad5 titers were comparable and all three superior to Ad5/
Ad5 and A5 alone (DNA/Ad5,Ad28/Ad5,Ad35/
Ad5,Ad5H43/Ad5.Ad5/Ad5,2/Ad5, p,0.05). Excepting
Ad5/Ad5, PyCSP-specific titers were enhanced .30 fold by the
boost in the prime-boost regimens (Figure 6c).
ICS analysis confirmed that PyCSP-specific CD3+CD8+ cells
were the primary responders, with minimal PyCSP-specific
Figure 5. Ad5PyCSP.H(43 m-43) induces T cells responses similar to Ad5PyCSP in naı¨ve mice and is not inhibited by Ad5 NAb in
vivo. Naı¨ve BALB/c mice or mice pre-immunized with two injections (161010 pu each) of Ad5 vector or an Ad5 vector containing the Ad35 fiber, were
immunized with Ad5PyCSP, or hexon-modified vector Ad5PyCSP.H(43 m-43) (n = 6 mice/group). PyCSP-specific T cell responses were assessed by
Intracellular cytokine staining (ICS) and IFNc ELISpot four weeks after immunization. Targets were MHC-matched A20.2J cells pulsed with synthetic
peptides representing the immunodominant CD8+ T cell epitope (PyCSP280–288) or CD4+ T cell epitope with nested subdominant CD8+ T cell
epitope (PyCSP57–70) from PyCSP or a defined CD8+ T cell epitope for the influenza virus hemagglutinin antigen (HA 332–340). (A) Schematic of the
experiment. (B) ICS analysis of CD8+ IFNc+ T cell responses from immunized mice assayed individually. Error bars indicate the standard error of the
mean, n = 6. (C) IFNc ELISpot responses from pooled splenocytes (250,000 cells/well). Error bars indicate the standard deviation of the mean from
quadruplicate samples. (D) ELISA against recombinant PyCSP protein capture antigen. Box-and-whisker plot with values for individual mice shown
(n = 6). The mean is indicated by the red line. * indicates groups where titers from all mice were ,8.
doi:10.1371/journal.pone.0033920.g005
Hexon Modified Ad Vector
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CD3+CD4+ responses (data not shown). Similar to the ELISpot
data, the CD8+ recall responses to the PyCSP280–288 (Figure 7)
and PyCSP280–296 (data not shown) peptides were robust, but
low to the CD4+ dominant and CD4+ and CD8+ subdominant
epitopes (data not shown). CD8+ responses were largely IFNc+ or
IFNc+TNFa+ populations. Minor CD8+IFNc+TNFa+IL2+ multi-
functional populations were observed (Figure 7), but did not
correlate with protection. PyCSP-specific CD4+ cytokine responses
were poor, limited to IFNc+ or TNFa+ producers, present in only
some mice/group, and were not multifunctional (IFNc+TN-
Fa+IL2+)(data not shown).
Discussion
Ad5-based vectors are capable of generating robust and
protective T cell and antibody responses in animal models and
are currently being evaluated in clinical trials for HIV [20] and
malaria [24,25,26]. However, the high prevalence of NAb to Ad5
in the human population, particularly in the developing world
[29,30,31] has the potential to limit the effectiveness of Ad5-based
vaccines. The majority of serotype-specific NAb recognize
determinants on the hexon and fiber capsid proteins [43,44],
and hexon-specific NAb appear to be the most prevalent and
potent in vivo [31,45,46]. Epitopes targeted by these hexon-specific
NAb have been mapped to the hypervariable domains of the
hexon protein, contained within exposed loops at the surface of the
capsid [46,53].
We have developed a hexon-modified adenovector vaccine
platform for malaria vaccine development that avoids the problem
of pre-existing anti-adenovirus immunity prevalent in human
populations. We were able to modify the determinants of NAb on
the Ad5 hexon so that anti-Ad5 NAb could not neutralize the
hexon-modified vector efficiently in vivo. Accordingly, we deleted
the hypervariable loops from the hexon protein within an Ad5
adenovector vaccine and replaced them with the loops derived
from selected serotypes with low prevalence in humans. We
substituted the Ad5 FG1 hypervariable loop with loops from Ad2
(group C), Ad34 (group B) and Ad43 (group D) adenoviruses. We
also attempted to substitute the large DE1 loop in its entirety with
loops from Ad2, Ad34 and Ad43, but only the Ad2 hypervariable
loop swap was capable of being converted into a virus vector.
Thus, the Ad5 capsid displayed considerable tolerance to
modifications in the FG1 loop and is less flexible in accommo-
dating modifications in the DE1 loop. We were able to specifically
substitute the HVRs in the Ad5 DE1 loop with Ad43 HVRs by
retaining the Ad5 derived non-HVR residues. Thus, we have
generated a chimeric Ad5 vector containing all nine HVRs from
the non-prevalent Ad43 serotype. Although Ad5 fiber-specific
neutralizing antibodies were capable of neutralizing this vector in
vitro, they did not limit the induction of antigen-specific antibody
Figure 6. Prime boost immunogenicity studies. BALB/c mice (n = 20 mice/group) were immunized with DNA or adenovectors as indicated. (A)
Schematic of the experiment. (B) PyCSP-specific T cell responses were assessed from a subset of the mice (n = 6) by IFNc ELISpot two weeks after
immunization. Targets were MHC-matched A20.2J cells pulsed with synthetic peptides representing the immunodominant CD8+ T cell epitope
(PyCSP280–288), CD4+ T cell epitope with nested CD8+ T cell epitope (PyCSP280–296), the immunodominant CD4+ T cell epitope (PyCSP57–70), the
subdominant CD8+ T cell epitope (PyCSP58–67), and CD4+ T cell epitope with nested CD8+ T cell epitope (PyCSP58–79) from PyCSP. Negative control
values were subtracted from reported data. Error bars indicate the standard deviation of the mean from quadruplicate samples. (C) ELISA against
PyCSP repeat peptide capture antigen. Error bars indicate the standard error of the mean.
doi:10.1371/journal.pone.0033920.g006
Figure 7. Polyfunctional T cell responses following different vaccine regimens. Splenocytes from mice immunized as in Figure 6 (n = 6)
were analyzed for polyfunctional CD8+ T cell responses following stimulation with A20.2J cells pulsed with a synthetic peptide representing the
immunodominant CD8+ T cell epitope (PyCSP280–288). Responses were measured by ICS for IFNc, IL-2 and TNFa. Black bars indicate the mean
percentage of cells positive for each combination of cytokines. Responses from individual animals are shown by the colored dots. (g = IFNc, 2 = IL2,
t = TNFa). Pie charts indicate the fraction of the total response comprising cells expressing each of the seven possible combinations of IFNc, IL-2 and
TNFa.
doi:10.1371/journal.pone.0033920.g007
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or T cell responses in mice immunized with this vector. This is
consistent with previous reports suggesting that Ad5 fiber-specific
neutralizing antibody does not inhibit Ad5 vector induced immune
responses [31,35,45,46,52]. The differential capacity of anti-hexon
and anti-fiber NAb to blunt the immunogenicity of Ad5-based
vectors in vivo is not understood, but may be related to their
different mechanisms of action. Anti-hexon NAb function by a
rapid single-hit kinetic mechanism and can neutralize virus already
attached to cells. In contrast, anti-fiber NAb function with slower
kinetics and exclusively function prior to cell attachment [54].
Prime-boost regimens have been used with great success in
many disease models and this strategy may be needed to achieve
optimal immune responses to prevent or control Plasmodium
infection. We have previously shown that a booster administration
of Ad5 vector was capable of boosting Ad5 primed antigen-specific
antibody responses in mice, but did not boost T cell responses
[55]. However, Ad5 vectors can efficiently boost T cell responses
primed by heterologous Ad vectors, including Ad35 [17]. Here we
show that our hexon-modified vector could be paired with an
unmodified Ad5 vector in prime-boost regimens and induced
more robust T cell responses than either vector by itself when the
vectors were administered at low doses. At higher doses of vector
(16109 pu) this heterologous prime-boost regimen provided
significant protection in the P. yoelii challenge model where the
single Ad5 vector or a homologous Ad5 prime-boost regimen did
not protect efficiently. However, at these high doses of vector, the
heterologous prime-boost regimens did not effectively boost T cell
responses relative to a single administration of Ad5.
Previously, Tsuji and colleagues demonstrated that Ad5 vectors
expressing PyCSP can provide protection against experimental
challenge with P. yoelii sporozoites [12,17,18]. Protection was
dependent on CD8+ T cells [12,17,18], but not on IFNc
[12,17,18] as depletion of CD8+ T cells abrogated protection
and the vaccine protected mice deficient in IFNc or the receptor
for IFNc. Lower doses of Ad5 vectors do not sterilely protect mice
from P. yoelii challenge. With these low dose immunizations,
prime-boost regimens are required. About 50% of the mice in our
studies were sterilely protected from sporozoite challenge using the
heterologous adenovector prime-boost regimens, which is similar
to the level of protection we observed using DNA prime-Ad5 boost
regimens. It appears that IFNc expressing CD8+ T cells are not a
marker for protection as non-protective regimens including Ad5
vector alone or the homologous Ad5 vector prime-boost regimen
induced a similar frequency of IFNc expressing CD8+ T cells as
the protective heterologous prime-boost regimens. We also
examined expression of TNFa and IL-2 by PyCSP antigen-
specific T cells and observed no dramatic differences between
protected and unprotected groups.
It is clear that antibodies directed against the repeat region of
CSP can provide protection against malaria. In rodent and non-
human primate models, passive transfer of antibodies directed
against the repeat region of P. berghei, P. yoelii, and P. vivax CSPs
can protect from experimental challenge [56,57,58,59]. In this
study, CSP-specific antibody responses appeared to correlate with
protection as regimens that induced the highest levels of protection
(heterologous Ad and DNA prime-Ad boost) were associated with
higher CSP-specific antibody responses relative to regimens
showing poor protective responses (Ad5 vector alone or the
homologous Ad5 vector prime-boost regimen). Additional studies
need to be performed to determine the correlates of protection
following vaccination with these heterologous prime-boost regi-
mens in the P. yoelii model.
Our data suggest that hexon-modified vectors may be capable
of inducing more robust T cell and antibody responses in people
with high titers of Ad5 neutralizing antibody. Data from recent
HIV clinical trials indicate that adenovectors that are not inhibited
by high titers of pre-existing NAb may have an advantage with
respect to induction of T cell responses and vaccine efficacy. Pre-
existing Ad5 neutralizing antibody has been shown to reduce the
percentage of responders as well as the magnitude of T cell
responses in people vaccinated with Ad5-based vaccines
[20,21,22]. As data in animal models indicate that T cells are
required for protection against pre-erythrocytic stage malaria
[60,61], hexon-modified vectors may be more immunogenic and
efficacious in people with high titers of Ad5 neutralizing antibody.
Because of the high prevalence of NAb to Ad5 in human
populations, many groups are pursuing rare human [27,62] or
chimpanzee adenovirus serotypes [36,37] for vaccine delivery.
However, most if not all of the vectors derived from these
alternative serotypes have been shown to be less potent than Ad5
in inducing transgene-specific T cell and antibody responses.
Hexon-modified Ad5 vectors are a powerful alternative that can
provide the potency of Ad5 without the susceptibility to being
neutralized by highly prevalent Ad5 NAb. These vectors should be
advanced and tested for vaccine efficacy in the human
experimental challenge model.
Materials and Methods
Advector construction
Adenovirus vectors were generated by using our plasmid-based
adenovector construction system. Briefly, the recombinant Ad5
Table 1. Protective efficacy of adenovector prime-boost regimens.
Prime Boost # Protected # Challenged % Protected P value
None Ad5CSP 0 14 0% n/a
Ad5CSP Ad5CSP 2 14 14% 0.1057
DNA-CSP Ad5CSP 10 28 36% 0.0007
Ad5CSP.H(43 m-43) Ad5CSP 6 14 43% 0.0006
Ad28CSP Ad5CSP 15 28 54% ,0.0001
Ad35CSP Ad5CSP 13 28 46% ,0.0001
Ad28Null Ad5Null 0 28 0% 1
DNA dose = 100 mg.
Ad dose = 16109 pu.
Fischer’s Exact Test, two-tailed versus Ad Null group.
doi:10.1371/journal.pone.0033920.t001
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genomes (containing a transgene expression cassette and hexon
modification) were liberated from plasmids by digestion with Pac I
restriction endonuclease, which cleaves adjacent to the inverted
terminal repeats (ITR) of the Ad5 genome. This vector DNA was
transfected into monolayer 293-ORF6 cells [1,2,3,4,5] and cell
lysates were serially passaged every three days until cytopathic
effect (CPE) was observed. CPE is an early indication that the viral
vector is growing in the complementing cell line. The CPE lysates
were expanded in four 10 cm plates and the cell lysates harvested
three days later. The expanded cell lysates were analyzed to
determine infectious vector particle concentration, analyzed by
PCR to insure vector genomic integrity and used to seed a
production run in suspension 293-ORF6 cells in shaker flasks
using serum-free media. Three days after infection the recombi-
nant vectors were released from infected cells by three cycles of
freeze-thawing, treated with benzonase, purified by banding on
three successive CsCl gradients, dialyzed into final formulation
buffer and stored at 280uC. Physical particle units (pu) were
determined by absorbance at 260 nm following disruption of the
capsid with SDS.
The specific modifications to the Ad5 hexon in the Ad5H(43 m-
43) vectors is described below. The HVR1 residues from Ad5
between and including AA136 through AA165 were deleted and
replaced with the Ad43 HVR1 amino acids from AA136 through
153. The HVR2 residues from Ad5 between and including AA190
through AA192 were deleted and replaced with the Ad43 HVR2
amino acids from AA178 through 184. The HVR3 residues from
Ad5 between and including AA212 through AA218 were deleted
and replaced with the Ad43 HVR3 amino acids from AA204
through 209. The HVR4 residues from Ad5 between and
including AA252 through AA258 were deleted and replaced with
the Ad43 HVR4 amino acids from AA244 through 251. The
HVR5 residues from Ad5 between and including AA271 through
AA279 were deleted and replaced with the Ad43 HVR5 amino
acids from AA264 through 271. The HVR6 residues from Ad5
between and including AA305 through AA310 were deleted and
replaced with the Ad43 HVR6 amino acids from AA279 through
302. The HVR7 residues from Ad5 between and including AA418
through AA428 were deleted and replaced with the Ad43 HVR7
amino acids from AA410 through 420. The HVR8 residues from
Ad5, AA435 through AA436, were deleted as the corresponding
region in Ad43 does not contain these amino acids. The HVR9
residues from Ad5 between and including AA440 through AA451
were deleted and replaced with the Ad43 HVR9 amino acids from
AA430 through 440.
The specific amino acid sequences of the modified regions of the
hexon proteins used in this study are shown in Figures S1 and S2.
For the Ad5H(2-2) chimera, the DE1 loop containing HVRs 1–6
of Ad5 (Ad5 hexon AA 132–315) and the FG1 loop containing
HVRs 7–9 from Ad5 (Ad5 hexon AA 420–449) were replaced with
the corresponding loops from Ad2 (Ad2 hexon AA 132–327 and
Ad2 hexon AA 432–465). Similarly, the Ad5H(43–43) and
Ad5H(34–34) chimeras contain deletions in the DE1 loop
containing HVRs 1–6 of Ad5 (Ad5 hexon AA 132–315) and the
FG1 loop containing HVRs 7–9 from Ad5 (Ad5 hexon AA 420–
449). These loops were replaced with the corresponding loops
from Ad43 and Ad34 respectively.
Animals
Female 5 to 8 week old BALB/c AnNCr mice were purchased
from either Harlan (Indianapolis, IN) or the National Cancer
Institute (Frederick, MD). All rabbit studies reported herein were
conducted under contract at Spring Valley (Woodbine, MD) in
1.5–2.5 kg (,6 week old), female, New Zealand white rabbits
purchased from Harlan.
Neutralizing antibody assay
Our neutralizing antibody assay is based on the capacity of
antibodies to neutralize adenovectors that express luciferase and is
similar to that described by Sprangers et al., 2003 [63]. First,
hexon-modified vectors that express luciferase were titrated to
determine the dose response curve for luciferase activity. A549
cells (American Type Culture Collection (ATCC) Manassas, VA)
were infected with these vectors and a control Ad5-based vector
that expresses luciferase (Ad5L) at multiplicities of infection (MOI)
between 10 and 4000 pu/cell. Luciferase activity was monitored
from cell lysates harvested 24 hours after infection. The luciferase
curves generated by the hexon-modified vectors were similar to
the control Ad5-based vector. Next we used the newly constructed
luciferase-expressing chimeras at an MOI in the linear range of the
assay, typically 500 pu/cell, to determine whether Ad5 NAb is
capable of neutralizing these chimeric hexon-containing vectors.
High titer Ad5 NAb sera were generated in mice and rabbits.
BALB/c mice or NZW rabbits were primed with 161010 pu of
adenovector and then boosted with 161010 pu of the same vector
4 weeks after the prime. Three weeks after the boost, blood was
collected by cardiac puncture, allowed to clot at room tempera-
ture, and the serum collected and frozen at 280uC for subsequent
use in the Ad5 NAb assay. Ad5 NAb were generated using Ad5,
and hexon-specific Ad5 Nab were generated using a chimeric Ad5
vector that contains an Ad35 fiber, Ad5.F(35). Rabbit Ad5 NAb
sera were prepared at Spring Valley Laboratories Inc., Woodbine,
MD.
Pooled serum from 30 immunized mice, six individual rabbits,
or individual humans was heat inactivated at 56uC for 60 minutes,
serially diluted and mixed with the luciferase expressing adeno-
vectors. After a 30 minute incubation at room temperature, the
virus/serum mixture was used to infect A549 cells seeded on 96
well plates. Luciferase activity from individual wells was measured
using a 96 well luminometer and the highest dilution of serum that
resulted in 90% inhibition of luciferase activity was determined.
We used a one tailed Paired Sample Wilcoxon Signed Rank test
to compare NAb titers in rabbit and human serum samples
obtained with the four reporter adenovectors; Ad5L,
Ad5L.H(43 m-43), Ad5L. F(35) and Ad5L.H(43 m-43).F(35). P
values of less than 0.05 were considered significant.
Immunizations
BALB/c mice were immunized with PfCSP expressing
adenovirus vector in a 0.1 ml volume by IM immunization
(bilateral injections into tibialis anterior muscles with a 29G1/2
needle). Immunizations to generate pre-existing Ad5 neutralizing
antibodies occurred by IM injection of adenovector into the left
gastrocnemius muscle (161010 pu) followed by a booster immu-
nization with the same vector (161010 pu) given 4 weeks later.
These doses were selected based on results of dose titration studies.
Experiments include groups of mice immunized with adenovector
without the gene of interest (AdNull) or containing an irrelevant
gene (Ad.L) and naı¨ve non-immunized negative control mice.
NZW rabbits (N = 6/group) were immunized by two 0.5 ml
injections into the right quadricep muscles with 161010 particles of
adenovirus vector using a 26G needle.
Immunological Assays
Cellular immune responses were assessed by ex vivo IFNc
ELISpot assays (N = 6 mice/group, assayed in pools) or intracel-
lular cytokine staining assays (N = 6 mice/group, assayed individ-
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ually) as described previously [55], using splenocytes harvested
from immunized or control mice as effector cells. Targets were
MHC-matched A20.2J cells pulsed with synthetic peptides.
ELISpot. Splenocytes (group pools, tested in quadruplicate)
were stimulated with peptide-loaded A20 cells for 36 hours.
Target cells pulsed with an irrelevant peptide and unpulsed target
cells served as negative controls. The number of IFNc secreting
cells, visualized as spots, was determined using an ELISpot Reader
(AID, Autoimmun Diagnostika). Data are presented as the mean
spot forming cells (SFC) 6 standard deviation.
ICS. 16106 splenocytes/mouse were stained for viability,
CD3, CD4, CD8, IL-2, IFNc, and TNFa. Splenocytes + peptide-
loaded A20 cells were incubated for 2 hours, golgi-inhibited,
incubated another 6 hr and then stained and fixed. All available
cells were acquired (LSRII, BD Biosciences), then analyzed with
FlowJo (Mac OSX version 8.8.6). Data are presented as mean
percent cytokine-producers of total CD3+CD8+ T cells. Individual
mouse data tested in singleton are represented as a single dot
overlapping the mean. Statistical analysis of ICS data was
performed using one way analysis of variance (ANOVA)
followed by Bonferroni’s means comparison test. P values of less
than 0.05 were considered significant.
Multifunctional T cell analyses were graphed in SPICE, version
5.
Analysis and presentation of distributions was performed using
SPICE version 5.2, downloaded from http://exon.niaid.nih.gov
[64]. Comparison of distributions was performed using a Student’s
T test and a partial permutation test as described [64].
ELISA. Antibody responses were assayed by ELISA as
described previously [55] against either PyCSP recombinant
protein capture antigen or PyCSP repeat peptide(QGPGAP)
using sera, assayed individually, from immunized or control
mice. Endpoint titration PyCSP-specific antibody titers (OD 0.5)
are shown, based on two-fold dilution curves of mouse serum
(triplicate wells).
Ethics Statement
The animal experiments reported herein as detailed in
GenVec’s Master Experimental Protocol (MP-BRU-8036-4-23-
2007) were reviewed and approved by the GenVec Institutional
Animal Care and Use Committee (IACUC). GenVec’s IACUC
ensures that all in vivo experimental protocols undergo a thorough
review process to assure that all in vivo experiments conducted
comply with all Animal Welfare Regulations and in accordance
with the principles set forth in the ‘‘Guide for the Care and Use of
Laboratory Animals’’. GenVec’s Animal Welfare Assurance
number is A4398-01.
Supporting Information
Figure S1 Amino acid sequences of the vectors shown in
Figure 1. The amino acid sequences of the DE1 and FG1 loops,
between and including position 126 through 461 of the Ad5 and
specific chimeric hexons are indicated. Red highlighted amino
acids indicate hypervariable regions of the Ad5 hexon [48]. Strike-
through lines indicate amino acids that are not resolved in the Ad5
crystal structure. Underlined residues indicate amino acids that are
different from Ad5 in the chimeras.
(TIF)
Figure S2 Amino acid sequences of the vectors shown in
Figure 2. The amino acid sequences of the DE1 and FG1 loops,
between and including positions 126 through 461 of the Ad5 and
specific chimeric hexons are indicated. Yellow highlighted regions
indicate Ad5 amino acid residues that are replaced with amino
acids from Ad43 in the H(43 m-43) chimeric hexon. Underlined
residues are amino acids that are different from Ad5.
(TIF)
Figure S3 Capsid protein composition of wild-type Ad5,
Ad5 vector and hexon-modified vectors by silver stain-
ing. 26109 particles of wild-type Ad5, lane 2; AdPyCSP, lane 3;
AdPyCSP.H(5–43), lane 4; AdPyCSP.H(43 m-5), lane 5; Ad-
PyCSP.H(43 m-43), lane 6; were electrophoresed on a 4–12%
SDS-polyacrylamide gel and proteins were stained with silver.
Molecular weight markers were run in the first lane and their
weights are indicated. The specific adenovirus proteins that
correspond to the prevalent bands are indicated.
(TIF)
Figure S4 Neutralization curves for Ad5L and
Ad5L.H(43 m-43). Sera obtained from mice immunized with
an Ad5 vector, Ad5 (A) or an Ad5 vector with an Ad35 fiber
replacement, Ad5.F35 (B) were diluted 1:48 and then 3-fold serial
dilutions were tested for neutralizing activity toward an unmod-
ified Ad5L vector and the Ad5L.H(43 m-43) hexon-modified
vector.
(EPS)
Figure S5 Hexon-modified vector efficiently boosts Ad5
vector primed T cell and antibody responses. BALB/c
mice were first primed with 16106 pu (A) or 16107 pu (B) of
Ad5PyCSP and boosted with the same dose of Ad5-
PyCSP.H(43 m-43) four weeks later. Controls included mice that
were immunized with a single dose of Ad5PyCSP at day 0 or a
single dose of Ad5PyCSP.H(43 m-43) administered at day 28.
CD8+ IFNc+ T cell responses were assessed two weeks after boost
by ICS. (C) PyCSP specific antibody responses were analyzed by
ELISA from sera collected 2 weeks after boost.
(TIF)
Table S1 Physical vector particle: Active particle ratios
(Pu/ffu) for adenovectors used in this study are shown.
(DOCX)
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